electroCore Announces Full Enrollment of TR-VENUS study of Non-Invasive Vagal Nerve Stimulation (nVNS) for the Acute Treatment of Stroke

NEXT STORY
NeurMedix Obtains FDA Authorization for Pivotal Phase 3 Alzheimer’s Trial
PREV STORY
Arch Biopartners Receives Ethics Committee Approval in Turkey to Dose Additional Patients in the Phase II Trial for LSALT Peptide
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Faron Pharmaceuticals Oy: FDA grants Fast Track Designation to Faron for Traumakine®

Faron Pharmaceuticals Ltd("Faron" or the "Company") FDA grants Fast Track Designation to Faron for ...

author_avatar
NASDAQ Market News

In Vitro Diagnostics (IVD) Market is expected to reach $91.3 billion in 2025 | CAGR 4.46%

In Vitro Diagnostics (IVD) Market is likely to garner $ 91.3 billion in 2025, ...

author_avatar
NASDAQ Market News

Celsion to Host Research and Development Update October 12, 2017

LAWRENCEVILLE, N.J., Oct. 04, 2017 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ:CLSN), an oncology development ...

author_avatar
NASDAQ Market News